BIOPHTA lève 6,5 mil
BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique
03 juin 2024 00h00 HE | Biophta
COMMUNIQUÉ DE PRESSE BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique Ce tour de table a été réalisé par UI Investissement (via le...
Logo-Biophta-rgb1.png
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
03 juin 2024 00h00 HE | Biophta
PRESS RELEASE BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage The seed round was co-led by UI Investissement (via the...
US Retinal Specialis
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
19 mars 2024 14h20 HE | Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
01 juin 2023 05h09 HE | Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
TIP_link_300x300.jpg
$12+ Billion Diabetic Retinopathy Market Size to Grow at a CAGR of 6.5% by 2028 | The Insight Partners
19 oct. 2022 10h09 HE | The Insight Partners
New York, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest market study on "Diabetic Retinopathy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19...
eyepoint logo.png
pSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
13 juin 2017 07h00 HE | pSivida Corp
Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence Conference Call Today at 4:30 p.m.ET WATERTOWN, Mass.,...